被称为现代光动力医学之父的美国Roswell Park癌症研究所(Roswell Park Cancer Institute,RPCI)光动力中心终身主任Thomas J.Dougherty博士于2018年10月不幸病逝。Dougherty在上世纪七十年代研发的Photofrin是全球第一个获得批证的用于...被称为现代光动力医学之父的美国Roswell Park癌症研究所(Roswell Park Cancer Institute,RPCI)光动力中心终身主任Thomas J.Dougherty博士于2018年10月不幸病逝。Dougherty在上世纪七十年代研发的Photofrin是全球第一个获得批证的用于肿瘤光动力疗法的光敏剂,目前仍在欧美和亚洲部分国家和地区使用。他的工作也是现代光动力医学的一个重要里程碑。根据Dougherty本人以及和他共事过的美国同事提供的资料,本文对Dougherty博士和Photofrin研发过程中的一些重要历史人物和事件做一回顾性介绍。展开更多
Background: The radiosensitizing effect of Photofrin II has been demonstrated in vitro and in animal models, even in tumor models known to be highly radioresistant, such as glioblastoma and bladder carcinoma. Radio-ad...Background: The radiosensitizing effect of Photofrin II has been demonstrated in vitro and in animal models, even in tumor models known to be highly radioresistant, such as glioblastoma and bladder carcinoma. Radio-adaptive doses are also known to lead to an augmented cell or tissue reaction. The aim of this study was to investigate potential synergistic or additive effects when combining the two methods in vitro for an improved therapeutic concept in bladder cancer. Material and Methods: RT4 human bladder carcinoma cell line and HCV29 human bladder epithelium cells were seeded and incubated with various concentrations of Photofrin II. The cells were additionally irradiated with ionizing radiation (0.05 Gy/2 Gy/0.05 Gy + 2 Gy). Cells without Photofrin II incubation and irradiation served as controls. The cell survival was evaluated. Results: The survival rate of both cell lines, RT4 and HCV29, did not differ significantly when incubated with a non-toxic concentration of Photofrin II and exposed to a pre-irradiation dose of 0.05 Gy prior to the 2 Gy radiation fraction, compared to cells exposed to Photofrin II plus a 2 Gy ionizing radiation. Conclusion: The combination of both methods did neither demonstrate a synergistic or additive effect nor did it lead to a negative influence of both modulating factors in an in vitro setting.展开更多
文摘被称为现代光动力医学之父的美国Roswell Park癌症研究所(Roswell Park Cancer Institute,RPCI)光动力中心终身主任Thomas J.Dougherty博士于2018年10月不幸病逝。Dougherty在上世纪七十年代研发的Photofrin是全球第一个获得批证的用于肿瘤光动力疗法的光敏剂,目前仍在欧美和亚洲部分国家和地区使用。他的工作也是现代光动力医学的一个重要里程碑。根据Dougherty本人以及和他共事过的美国同事提供的资料,本文对Dougherty博士和Photofrin研发过程中的一些重要历史人物和事件做一回顾性介绍。
文摘Background: The radiosensitizing effect of Photofrin II has been demonstrated in vitro and in animal models, even in tumor models known to be highly radioresistant, such as glioblastoma and bladder carcinoma. Radio-adaptive doses are also known to lead to an augmented cell or tissue reaction. The aim of this study was to investigate potential synergistic or additive effects when combining the two methods in vitro for an improved therapeutic concept in bladder cancer. Material and Methods: RT4 human bladder carcinoma cell line and HCV29 human bladder epithelium cells were seeded and incubated with various concentrations of Photofrin II. The cells were additionally irradiated with ionizing radiation (0.05 Gy/2 Gy/0.05 Gy + 2 Gy). Cells without Photofrin II incubation and irradiation served as controls. The cell survival was evaluated. Results: The survival rate of both cell lines, RT4 and HCV29, did not differ significantly when incubated with a non-toxic concentration of Photofrin II and exposed to a pre-irradiation dose of 0.05 Gy prior to the 2 Gy radiation fraction, compared to cells exposed to Photofrin II plus a 2 Gy ionizing radiation. Conclusion: The combination of both methods did neither demonstrate a synergistic or additive effect nor did it lead to a negative influence of both modulating factors in an in vitro setting.
